Posted by Michael Wonder on 24 Nov 2021
ICER to assess gene therapy for beta thalassaemia
24 November 2021 - Report will be subject of New England CEPAC meeting in June 2022; draft scoping document open to public comment until 16 December 2021.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of betibeglogene autotemcel (Zynteglo/LentiGlobin, bluebird bio) for the treatment of beta thalassaemia.
